Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Prevention of late-life depression: a framework and prospectus for research

Neuropsychopharmacology (2026)Cite this article

Subjects

Abstract

Depression is a leading cause of disease burden, disability, and distress for millions of older adults. Therefore, prevention of late-life depression (LLD) is a research and public health priority. Much of the research on depression prevention has been guided by the central framework of prevention of mental disorders that was developed by the National Academies of Medicine (NAM). This framework features three modes of prevention, centered on the group or people at risk: 1) indicated prevention, which focuses on those who have symptoms but are below the threshold of clinical disease; 2) selective prevention, which focuses on persons at higher risk to develop a disease because of having key risk factors; 3) universal prevention, which focuses on the population as a whole, regardless of risk factors or risk status. This perspective will provide illustrative examples of all three NAM modes of prevention, including one example from the author’s work that simultaneously addressed indicated, selective, and universal prevention of late-life depression in the VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP) study. This paper will also discuss next steps in research to advance LLD prevention, with a view toward ensuring that all older adults can benefit from the increasing range of prevention options available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Committee on Prevention of Mental Disorders: Institute of Medicine. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, DC: National Academy Press; 1994.

  2. Centers for Disease Control. A framework for assessing the effectiveness of disease and injury prevention. MMWR. 1992;41:1–12.

  3. Buntrock C, Harrer M, Sprenger AA, Illing S, Sakata M, Furukawa TA, et al. Psychological interventions to prevent the onset of major depression in adults: a systematic review and individual participant data meta-analysis. Lancet Psychiatry. 2024;11:990–1001.

    Article  PubMed  Google Scholar 

  4. Cuijpers P, van Straten A, Smit F, Mihalopoulos C, Beekman A. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry. 2008;165:1272–80.

    Article  PubMed  Google Scholar 

  5. Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, et al. Effect of aspirin vs placebo on the prevention of depression in older people: a randomized clinical trial. JAMA Psychiatry. 2020;77:1012–20.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bot M, Brouwer IA, Roca M, Kohls E, Penninx B, Watkins E, et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA. 2019;321:858–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Okereke OI, Reynolds CF III, Mischoulon D, Chang G, Vyas CM, Cook NR, et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2020;324:471–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Okereke OI, Reynolds CF, Mischoulon D, Chang GC, Cook NR, Copeland T, et al. The VITamin D and OmegA-3 trial-depression endpoint prevention (VITAL-DEP): rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. Contemp Clin Trials. 2018;68:133–45.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lyness JM, Heo M, Datto CJ, Ten Have TR, Katz IR, Drayer R, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med. 2006;144:496–504.

    Article  PubMed  Google Scholar 

  10. Lyness JM, Kim J, Tang W, Tu X, Conwell Y, King DA, et al. The clinical significance of subsyndromal depression in older primary care patients. Am J Geriatr Psychiatry. 2007;15:214–23.

    Article  PubMed  Google Scholar 

  11. van’t Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, van Hout HP, van der Horst HE, Cuijpers P, et al. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry. 2009;66:297–304.

    Article  PubMed  Google Scholar 

  12. Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker TR, Davidson KW, et al. Screening for depression and suicide risk in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:2057–67.

    Article  PubMed  Google Scholar 

  13. Schoevers RA, Smit F, Deeg DJ, Cuijpers P, Dekker J, van Tilburg W, et al. Prevention of late-life depression in primary care: Do we know where to begin?. Am J Psychiatry. 2006;163:1611–21.

    Article  PubMed  Google Scholar 

  14. Chang SC, Pan A, Kawachi I, Okereke OI. Risk factors for late-life depression: a prospective cohort study among older women. Prev Med. 2016;91:144–51.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rovner BW, Casten RJ, Hegel MT, Leiby BE, Tasman WS. Preventing depression in age-related macular degeneration. Arch Gen Psychiatry. 2007;64:886–92.

    Article  PubMed  Google Scholar 

  16. Irwin MR, Carrillo C, Sadeghi N, Bjurstrom MF, Breen EC, Olmstead R. Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial. JAMA Psychiatry. 2022;79:33–41.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sánchez-Villegas A, Martínez-González MA, Estruch R, Salas-Salvadó J, Corella D, Covas MI, et al. Mediterranean dietary pattern and depression: the PREDIMED randomized trial. BMC Med. 2013;11:208.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry. 2016;173:221–31.

    Article  PubMed  Google Scholar 

  19. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–6.

    Article  CAS  PubMed  Google Scholar 

  20. Sarkar S, Schaefer M. Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics. 2014;55:221–34.

    Article  PubMed  Google Scholar 

  21. Collins LM, Murphy SA, Nair VN, Strecher VJ. A strategy for optimizing and evaluating behavioral interventions. Ann Behav Med. 2005;30:65–73.

    Article  PubMed  Google Scholar 

  22. Baker LD, Espeland MA, Whitmer RA, Snyder HM, Leng X, Lovato L, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334:681–91.

  23. Cuijpers P. Examining the effects of prevention programs on the incidence of new cases of mental disorders: the lack of statistical power. Am J Psychiatry. 2003;160:1385–91.

    Article  PubMed  Google Scholar 

  24. Okereke OI, Lyness JM, Lotrich FE, Reynolds CF III. Depression in late-life: a focus on prevention. Focus (Am Psychiatr Publ). 2013;11:22–31.

    PubMed  PubMed Central  Google Scholar 

  25. Okereke OI, Vyas CM, Mischoulon D, Chang G, Cook NR, Weinberg A, et al. Effect of long-term supplementation with marine omega-3 fatty acids vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2021;326:2385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vyas CM, Mischoulon D, Chang G, Cook NR, Weinberg A, Copeland T, et al. Effects of vitamin D(3) and marine omega-3 fatty acids supplementation on indicated and selective prevention of depression in older adults: results from the clinical center sub-cohort of the VITamin D and omegA-3 triaL (VITAL). J Clin Psychiatry. 2023;84:22m14629.

  27. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163–73.

    Article  PubMed  Google Scholar 

  28. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med. 2006;21:547–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hepner KA, Morales LS, Hays RD, Edelen MO, Miranda J. Evaluating differential item functioning of the PRIME-MD mood module among impoverished black and white women in primary care. Women's Health Issues. 2008;18:53–61.

    Article  PubMed  Google Scholar 

  30. Gilbody S, Littlewood E, McMillan D, Chew-Graham CA, Bailey D, Gascoyne S, et al. Behavioural activation to prevent depression and loneliness among socially isolated older people with long-term conditions: The BASIL COVID-19 pilot randomised controlled trial. PLoS Med. 2021;18:e1003779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dias A, Azariah F, Anderson SJ, Sequeira M, Cohen A, Morse JQ, et al. Effect of a lay counselor intervention on prevention of major depression in older adults living in low- and middle-income countries: a randomized clinical trial. JAMA Psychiatry. 2019;76:13–20.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93:1261–7.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Gaugler JE, Baier RR, Baker ZG, Boltz M, Fortinsky RH, Gustavson AM, et al. Using hybrid effectiveness studies to facilitate implementation in community-based settings: three case studies in dementia care Research. J Am Med Dir Assoc. 2024;25:27–33.

    Article  PubMed  Google Scholar 

  34. Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, et al. Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet. 2022;399:957–1022.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Mass General Brigham, Boston, MA, USA

    Olivia I. Okereke

  2. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA

    Olivia I. Okereke

Authors
  1. Olivia I. Okereke
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Okereke is solely responsible for the conception or design of the work; drafted the work and revised it critically for important intellectual content; approved of the final version to be published; and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Olivia I. Okereke.

Ethics declarations

Competing interests

Okereke has received royalties from Springer Publishing for a book on late-life depression prevention.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okereke, O.I. Prevention of late-life depression: a framework and prospectus for research. Neuropsychopharmacol. (2026). https://doi.org/10.1038/s41386-026-02339-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41386-026-02339-9

This article is cited by

Search

Advanced search

Quick links